Full Report

Format

Full Report
Summary (Text)
Summary (XML)

Send to:

Choose Destination

File
Clipboard
Collections

ALK-positive anaplastic large cell lymphoma

MedGen UID:: 233117
•Concept ID:: C1332079
•: Neoplastic Process

Synonyms:	ALCL, ALK+; ALK+ ALCL; ALK+ anaplastic large cell lymphoma; ALK-Positive Anaplastic Large Cell Lymphoma; ALKoma; Anaplastic Large Cell Lymphoma, ALK-Positive; anaplastic large cell lymphoma, ALK-positive
Modes of inheritance:	Not genetically inherited MedGen UID: 988794 •Concept ID: CN307044 • Finding Source: Orphanet clinical entity without genetic inheritance. See: This record Not genetically inherited (Orphanet)

Monarch Initiative:	MONDO:0017602
Orphanet:	ORPHA300895

Definition

A type of ALCL, a rare and aggressive peripheral T-cell non-Hodgkin lymphoma affecting lymph nodes and extranodal sites, which is characterized by the expression of a protein called anaplastic lymphoma kinase (ALK). [from ORDO]

Term Hierarchy

GTR
MeSH

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVALK-positive anaplastic large cell lymphoma

Pathological process
- Disease
  - Neoplasm
    - Malignant neoplastic disease
      - Anaplastic cancer
        Anaplastic large cell lymphoma
        ALK-positive anaplastic large cell lymphoma
        Central Nervous System Anaplastic Large Cell Lymphoma, ALK-Positive
        Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Positive
        Recurrent Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Positive
        Refractory Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Positive

Professional guidelines

PubMed

Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents.

Rigaud C, Knörr F, Brugières L, Woessmann W
Best Pract Res Clin Haematol 2023 Mar;36(1):101444. Epub 2023 Feb 2 doi: 10.1016/j.beha.2023.101444. PMID: 36907641

Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease?

Rigaud C, Abbas R, Grand D, Minard-Colin V, Aladjidi N, Buchbinder N, Garnier N, Plat G, Couec ML, Duplan M, Lambilliotte A, Schmitt C, Leblanc T, Lamant L, Brugières L
Pediatr Blood Cancer 2021 Jun;68(6):e28982. Epub 2021 Mar 9 doi: 10.1002/pbc.28982. PMID: 33687135

Current management of peripheral T-cell lymphomas.

Gooptu M, Rhoades R, Pro B
Cancer Treat Res 2015;165:289-303. doi: 10.1007/978-3-319-13150-4_12. PMID: 25655615

See all (10)

Recent clinical studies

Etiology

Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).

Chen MT, Fu XH, Huang H, Wang Z, Fang XJ, Yao YY, Ren QG, Chen ZG, Lin TY
Leuk Lymphoma 2021 Mar;62(3):571-580. Epub 2020 Nov 6 doi: 10.1080/10428194.2020.1839658. PMID: 33155495

Therapeutic options in peripheral T cell lymphoma.

Zhang Y, Xu W, Liu H, Li J
J Hematol Oncol 2016 Apr 12;9:37. doi: 10.1186/s13045-016-0267-0. PMID: 27071634 Free PMC Article

ALK-positive anaplastic large cell lymphoma: an evolving story.

Bonzheim I, Steinhilber J, Fend F, Lamant L, Quintanilla-Martinez L
Front Biosci (Schol Ed) 2015 Jun 1;7(2):248-59. doi: 10.2741/S438. PMID: 25961700

Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK.

Damm-Welk C, Pillon M, Woessmann W, Mussolin L
Front Biosci (Schol Ed) 2015 Jun 1;7(2):205-16. doi: 10.2741/S434. PMID: 25961696

Allogeneic transplantation in T-cell lymphomas.

Schmitz N, Wu HS, Glass B
Semin Hematol 2014 Jan;51(1):67-72. Epub 2013 Nov 28 doi: 10.1053/j.seminhematol.2013.11.010. PMID: 24468318

See all (53)

Diagnosis

Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents.

Rigaud C, Knörr F, Brugières L, Woessmann W
Best Pract Res Clin Haematol 2023 Mar;36(1):101444. Epub 2023 Feb 2 doi: 10.1016/j.beha.2023.101444. PMID: 36907641

Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.

Brivio E, Baruchel A, Beishuizen A, Bourquin JP, Brown PA, Cooper T, Gore L, Kolb EA, Locatelli F, Maude SL, Mussai FJ, Vormoor-Bürger B, Vormoor J, von Stackelberg A, Zwaan CM
Eur J Cancer 2022 Mar;164:1-17. Epub 2022 Feb 1 doi: 10.1016/j.ejca.2021.12.029. PMID: 35121370

Coexpression of MCT1 and MCT4 in ALK-positive Anaplastic Large Cell Lymphoma: Diagnostic and Therapeutic Implications.

Choi JW, Lee Y, Kim H, Cho HY, Min SK, Kim YS
Am J Surg Pathol 2022 Feb 1;46(2):241-248. doi: 10.1097/PAS.0000000000001820. PMID: 34619707

ALK-positive anaplastic large cell lymphoma: an evolving story.

Bonzheim I, Steinhilber J, Fend F, Lamant L, Quintanilla-Martinez L
Front Biosci (Schol Ed) 2015 Jun 1;7(2):248-59. doi: 10.2741/S438. PMID: 25961700

Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK.

Damm-Welk C, Pillon M, Woessmann W, Mussolin L
Front Biosci (Schol Ed) 2015 Jun 1;7(2):205-16. doi: 10.2741/S434. PMID: 25961696

See all (92)

Therapy

Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial.

Brugières L, Cozic N, Houot R, Rigaud C, Sibon D, Arfi-Rouche J, Bories P, Cottereau AS, Delmer A, Ducassou S, Garnier N, Lamant L, Leruste A, Millot F, Moalla S, Morschhauser F, Nolla M, Pagnier A, Reguerre Y, Renaud L, Schmitt A, Simonin M, Verschuur A, Hoog Labouret N, Mahier Ait Oukhatar C, Vassal G
Eur J Cancer 2023 Sep;191:112984. Epub 2023 Jul 17 doi: 10.1016/j.ejca.2023.112984. PMID: 37549532

Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents.

Rigaud C, Knörr F, Brugières L, Woessmann W
Best Pract Res Clin Haematol 2023 Mar;36(1):101444. Epub 2023 Feb 2 doi: 10.1016/j.beha.2023.101444. PMID: 36907641

Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).

Chen MT, Fu XH, Huang H, Wang Z, Fang XJ, Yao YY, Ren QG, Chen ZG, Lin TY
Leuk Lymphoma 2021 Mar;62(3):571-580. Epub 2020 Nov 6 doi: 10.1080/10428194.2020.1839658. PMID: 33155495

Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.

Kim D, Koh Y, Yoon SS
Anticancer Res 2020 Mar;40(3):1395-1403. doi: 10.21873/anticanres.14081. PMID: 32132036

KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth.

Hwang J, Song I, Lee K, Kim HR, Hong EH, Hwang JS, Ahn SH, Lee J
Invest New Drugs 2020 Oct;38(5):1282-1291. Epub 2020 Jan 20 doi: 10.1007/s10637-020-00896-4. PMID: 31956933

See all (60)

Prognosis

Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents.

Rigaud C, Knörr F, Brugières L, Woessmann W
Best Pract Res Clin Haematol 2023 Mar;36(1):101444. Epub 2023 Feb 2 doi: 10.1016/j.beha.2023.101444. PMID: 36907641

Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.

Coexpression of MCT1 and MCT4 in ALK-positive Anaplastic Large Cell Lymphoma: Diagnostic and Therapeutic Implications.

Choi JW, Lee Y, Kim H, Cho HY, Min SK, Kim YS
Am J Surg Pathol 2022 Feb 1;46(2):241-248. doi: 10.1097/PAS.0000000000001820. PMID: 34619707

ALK-positive anaplastic large-cell lymphoma with primary bone involvement: A rare case and review of the literature.

Noh BJ, Han CS, Park JS, Lee J, Kim YW, Park YK
Malays J Pathol 2018 Aug;40(2):161-167. PMID: 30173234

Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK.

Damm-Welk C, Pillon M, Woessmann W, Mussolin L
Front Biosci (Schol Ed) 2015 Jun 1;7(2):205-16. doi: 10.2741/S434. PMID: 25961696

See all (71)

Clinical prediction guides

Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma project.

Chiattone C, Civallero M, Fischer T, Miranda E, Manni M, Zing NPC, Pileri SA, Montoto S, Horwitz SM, Cabrera ME, De Souza CA, Nagler A, Luminari S, Ferreri AJM, Carson KR, Re A, Rigacci L, Nassi L, Stepanishyna Y, Federico M, Inghirami G
Hematol Oncol 2022 Dec;40(5):953-961. Epub 2022 Sep 15 doi: 10.1002/hon.3074. PMID: 36083035

Coexpression of MCT1 and MCT4 in ALK-positive Anaplastic Large Cell Lymphoma: Diagnostic and Therapeutic Implications.

Choi JW, Lee Y, Kim H, Cho HY, Min SK, Kim YS
Am J Surg Pathol 2022 Feb 1;46(2):241-248. doi: 10.1097/PAS.0000000000001820. PMID: 34619707

Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.

Kim D, Koh Y, Yoon SS
Anticancer Res 2020 Mar;40(3):1395-1403. doi: 10.21873/anticanres.14081. PMID: 32132036

ALK-positive anaplastic large cell lymphoma: an evolving story.

Bonzheim I, Steinhilber J, Fend F, Lamant L, Quintanilla-Martinez L
Front Biosci (Schol Ed) 2015 Jun 1;7(2):248-59. doi: 10.2741/S438. PMID: 25961700

ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature.

Beltran B, Castillo J, Salas R, Quiñones P, Morales D, Hurtado F, Riva L, Winer E
J Hematol Oncol 2009 Feb 27;2:11. doi: 10.1186/1756-8722-2-11. PMID: 19250532 Free PMC Article

See all (43)

Recent systematic reviews

Diagnostic Challenge of Sarcomatoid Variant of ALK-Positive Anaplastic Large Cell Lymphoma: Case Report and Updated Systematic Literature Review.

Song F, Yu S, Jia M, Gao H, Sun PL
Int J Surg Pathol 2021 Sep;29(6):658-666. Epub 2021 Jan 11 doi: 10.1177/1066896920986967. PMID: 33427000

See all (1)

MedGen

National Center for Biotechnology Information

Send to:

ALK-positive anaplastic large cell lymphoma

Definition

Term Hierarchy

Professional guidelines

PubMed

Recent clinical studies

Etiology

Diagnosis

Therapy

Prognosis

Clinical prediction guides

Recent systematic reviews

Supplemental Content

Table of contents

Clinical resources

Practice guidelines

Consumer resources

Reviews

Related information

Recent activity